Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer
Vergote, I. González-Martin, A. Fujiwara, K. Kalbacher, E. Bagaméri, A. Ghamande, S. Lee, J. Y. Banerjee, S. Maluf, F. C. Lorusso, D.
Vergote, I.
González-Martin, A.
Fujiwara, K.
Kalbacher, E.
Bagaméri, A.
Ghamande, S.
Lee, J. Y.
Banerjee, S.
Maluf, F. C.
Lorusso, D.
Citations
Altmetric:
Abstract
Background Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy. Methods We conducted a phase 3, multinational, open-label trial of tisotumab vedotin as second- or third-line therapy in patients with recurrent or metastatic cervical cancer. Patients were randomly assigned, in a 1:1 ratio, to receive tisotumab vedotin monotherapy (2.0 mg per kilogram of body weight every 3 weeks) or the investigator's choice of chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed). The primary end point was overall survival. Results A total of 502 patients underwent randomization (253 were assigned to the tisotumab vedotin group and 249 to the chemotherapy group); the groups were similar with respect to demographic and disease characteristics. The median overall survival was significantly longer in the tisotumab vedotin group than in the chemotherapy group (11.5 months [95% confidence interval {CI}, 9.8 to 14.9] vs. 9.5 months [95% CI, 7.9 to 10.7]), results that represented a 30% lower risk of death with tisotumab vedotin than with chemotherapy (hazard ratio, 0.70; 95% CI, 0.54 to 0.89; two-sided P=0.004). The median progression-free survival was 4.2 months (95% CI, 4.0 to 4.4) with tisotumab vedotin and 2.9 months (95% CI, 2.6 to 3.1) with chemotherapy (hazard ratio, 0.67; 95% CI, 0.54 to 0.82; two-sided P<0.001). The confirmed objective response rate was 17.8% in the tisotumab vedotin group and 5.2% in the chemotherapy group (odds ratio, 4.0; 95% CI, 2.1 to 7.6; two-sided P<0.001). A total of 98.4% of patients in the tisotumab vedotin group and 99.2% in the chemotherapy group had at least one adverse event that occurred during the treatment period (defined as the period from day 1 of dose 1 until 30 days after the last dose); grade 3 or greater events occurred in 52.0% and 62.3%, respectively. A total of 14.8% of patients stopped tisotumab vedotin treatment because of toxic effects. Conclusions In patients with recurrent cervical cancer, second- or third-line treatment with tisotumab vedotin resulted in significantly greater efficacy than chemotherapy. (Funded by Genmab and Seagen [acquired by Pfizer]; innovaTV 301 ClinicalTrials.gov number, NCT04697628.)
Authors
Vergote, I.
González-Martin, A.
Fujiwara, K.
Kalbacher, E.
Bagaméri, A.
Ghamande, S.
Lee, J. Y.
Banerjee, S.
Maluf, F. C.
Lorusso, D.
Yonemori, K.
Van Nieuwenhuysen, E.
Manso, L.
Woelber, L.
Westermann, A.
Covens, A.
Hasegawa, K.
Kim, B. G.
Raimondo, M.
Bjurberg, M.
Cruz, F. M.
Angelergues, A.
Cibula, D.
Barraclough, Lisa
Oaknin, A.
Gennigens, C.
Nicacio, L.
Teng, M. S. L.
Whalley, E.
Soumaoro, I.
Slomovitz, B. M.
Innova, T. V. E. C. G. O. G. C.
González-Martin, A.
Fujiwara, K.
Kalbacher, E.
Bagaméri, A.
Ghamande, S.
Lee, J. Y.
Banerjee, S.
Maluf, F. C.
Lorusso, D.
Yonemori, K.
Van Nieuwenhuysen, E.
Manso, L.
Woelber, L.
Westermann, A.
Covens, A.
Hasegawa, K.
Kim, B. G.
Raimondo, M.
Bjurberg, M.
Cruz, F. M.
Angelergues, A.
Cibula, D.
Barraclough, Lisa
Oaknin, A.
Gennigens, C.
Nicacio, L.
Teng, M. S. L.
Whalley, E.
Soumaoro, I.
Slomovitz, B. M.
Innova, T. V. E. C. G. O. G. C.
Description
Date
2024
Publisher
Collections
Keywords
Type
Citation
Vergote I, González-Martin A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, et al. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. NEW ENGLAND JOURNAL OF MEDICINE. 2024 JUL 4;391(1):44-55. PubMed PMID: WOS:001272081300002. English.